forum
THYROCARE Share Price Target
Thyrocare Technologies Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
THYROCARE Share Price *
473 +2.25 (0.48%)
* (quote may be delayed)
THYROCARE Share Price Forecast - Consensus
| No. of reports in last year | 4 |
| No. of analysts | 2 |
| Average Consensus Forecast | 678.00 |
| Consensus Potential | 28.26% |
THYROCARE Share Price Target - Broker Reports - 2019
Karvy Stock Broking
22-Aug-19
Price @ Call: 439.77
Target: 526
BUY
We maintain a ‘BUY’ rating and value Thyrocare at 24.2x FY21E EPS of Rs. 21.7 for a target of Rs. 526. Weaker than expected performance of additional employees hired and further depreciation of INR could pose a threat to our call.
Prabhudas Lilladher
14-Aug-19
Price @ Call: 447.19
Target: 595
BUY
Q1 Sales inline; Focus on growth to stave off competition from start ups
The stock trades at PER of 23.8x and 21.5x FY20E and FY21E respectively. With favorable H2FY20E, we expect Thyrocare to at least 15% YoY growth in revenues and 15% YoY growth in PAT in FY20E as it focuses on EBITDA growth instead of profitability. Management guided that price rationalisations and advertisement (guided at 4-5% of sales) costs may impact EBITDA margin of its pathology business maximum by 400-500bps. While diagnostic companies is expected to trade at premium valuation with features of consumers business, Thyrocar valuation has been corrected by 36% in 12 months. With attractive valuation vs. peers, we maintain our earnings estimate and BUY rating with TP at Rs595.
The stock trades at PER of 23.8x and 21.5x FY20E and FY21E respectively. With favorable H2FY20E, we expect Thyrocare to at least 15% YoY growth in revenues and 15% YoY growth in PAT in FY20E as it focuses on EBITDA growth instead of profitability. Management guided that price rationalisations and advertisement (guided at 4-5% of sales) costs may impact EBITDA margin of its pathology business maximum by 400-500bps. While diagnostic companies is expected to trade at premium valuation with features of consumers business, Thyrocar valuation has been corrected by 36% in 12 months. With attractive valuation vs. peers, we maintain our earnings estimate and BUY rating with TP at Rs595.
Prabhudas Lilladher
12-Feb-19
Price @ Call: 490.87
Target: 795
BUY
THYROCARE Share Price Target - Broker Reports - 2018
Prabhudas Lilladher
12-Nov-18
Price @ Call: 550
Target: 796
BUY
Prabhudas Lilladher
14-Aug-18
Price @ Call: 600
Target: 795
BUY
Prabhudas Lilladher
6-Aug-18
Price @ Call: 626.3
Target: 795
BUY
JM Financial
4-May-18
Price @ Call: 647.22
Target: 780
BUY
Prabhudas Lilladher
4-May-18
Price @ Call: 654
Target: 795
BUY
Edelweiss
4-May-18
Price @ Call: 654
Target: 750
BUY
Edelweiss
15-Feb-18
Price @ Call: 656
Target: 750
BUY
THYROCARE Share Price Target - Broker Reports - 2017
Edelweiss
13-Dec-17
Price @ Call: 675.5
Target: 740
BUY
Prabhudas Lilladher
12-Dec-17
Price @ Call: 675
Target: 1067
BUY
THYROCARE Share Price Target - Broker Reports - 2016
Moneylicious
22-Nov-16
Price @ Call: 626.05
Target: 750
BUY
Prabhudas Lilladher
17-Nov-16
Price @ Call: 592
Target: 1067
BUY